期刊
ONCOGENE
卷 31, 期 4, 页码 527-534出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2011.252
关键词
breast cancer; degradation; ER alpha; RUNX3; tumor suppressor
资金
- UIUC
- NIH [DK-085158, CA116616, DK-071909]
- NATIONAL CANCER INSTITUTE [R01CA116616] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK071909, R01DK085158] Funding Source: NIH RePORTER
Transcription factor RUNX3 is inactivated in a number of malignancies, including breast cancer, and is suggested to function as a tumor suppressor. How RUNX3 functions as a tumor suppressor in breast cancer remains undefined. Here, we show that about 20% of female Runx3(+/-) mice spontaneously developed ductal carcinoma at an average age of 14.5 months. Additionally, RUNX3 inhibits the estrogen-dependent proliferation and transformation potential of ER alpha-positive MCF-7 breast cancer cells in liquid culture and in soft agar and suppresses the tumorigenicity of MCF-7 cells in severe combined immunodeficiency mice. Furthermore, RUNX3 inhibits ER alpha-dependent transactivation by reducing the stability of ER alpha. Consistent with its ability to regulate the levels of ER alpha, expression of RUNX3 inversely correlates with the expression of ER alpha in breast cancer cell lines, human breast cancer tissues and Runx3(+/-) mouse mammary tumors. By destabilizing ER alpha, RUNX3 acts as a novel tumor suppressor in breast cancer. Oncogene (2012) 31, 527-534; doi: 10.1038/onc.2011.252; published online 27 June 2011
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据